Two healthcare stocks, two plunging stock prices, and two unique scenarios heading into the end of 2019.
The American wind power industry has reached an important level of maturity, but that changes the game for investors.
Is Wall Street's initial excitement giving way to more realistic expectations?
It's a small correction, because each of these three stocks is down at least 13% since the beginning of the year due to fears of a supply glut.
The company filed its annual report for 2018 and gave a brief update on first-half 2019 operations.
A cyberattack resulted in a clinical trial delay. Really.
These two healthcare businesses are capturing formidable growth opportunities by executing in their overlooked niches.
A recent IPO and a small fertilizer producer appear to have been overlooked by Mr. Market, but individual investors might want to keep an eye on both.
Depending on one customer for too much revenue is generally a red flag, but the intentional growth strategy of Personalis is worth paying closer attention to.
These two companies generate plenty of cash flow to sustain -- and grow -- their dividend payouts for years to come.
Investors walked away from UroGen Pharma after an article was published by a short-seller, but clinical results appear to favor the company.
10X Genomics is growing revenue at a healthy clip, but a series of patent-infringement suits are hanging over the lab-hardware business.
The generic drug specialist raised money through a debt offering that might be a little more complicated than necessary.
Wall Street is questioning the value and purpose of a recent deal.
The volatile stock still has potential, but investors need the proper perspective for the slow-growing hardware business.
Management has expanded selling, general, and administrative expenses in lockstep with gross profit increases. The aggressive strategy has a cost.
The engineering and construction company is working with an outside consulting firm on a turnaround strategy. Those tend to be painful.
The company announced a stock offering to raise cash, but today's drop could've been much worse.
The business is raising cash through two offerings: one of debt and one of common stock.
Investors continue to sour on the solid oxide fuel cell developer.